Who
Nikita Shah
Executive Vice President
Company insider
Files Form 4 as: Executive Vice President, Amneal Pharmaceuticals.
In numbers
- Trades disclosed
- 142
- Buys
- 0
- Sells
- 11
- Bought
- $0
- Sold
- $11.6M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 7 May 2018
- Last trade
- 12 Aug 2026
- Last filed
- 13 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 Aug 2026filed 13 Aug 2026 | AMRX Amneal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $2.6M146,403 at $17.51 | filing |
| 12 Aug 2026filed 13 Aug 2026 | AMRX Amneal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $2.6M146,403 at $17.51 | filing |
| 4 Mar 2026filed 5 Mar 2026 | AMRX Amneal PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $239K17,976 at $13.30 | filing |
| 4 Mar 2026filed 5 Mar 2026 | AMRX Amneal Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —35,880 at $0.00 | filing |
| 4 Mar 2026filed 5 Mar 2026 | AMRX Amneal Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —35,880 at $0.00 | filing |
| 4 Mar 2026filed 5 Mar 2026 | AMRX Amneal PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | —35,880 | filing |
| 4 Mar 2026filed 5 Mar 2026 | AMRX Amneal PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $239K17,976 at $13.30 | filing |
| 4 Mar 2026filed 5 Mar 2026 | AMRX Amneal PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | —35,880 | filing |
| 3 Mar 2026filed 5 Mar 2026 | AMRX Amneal PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | —36,232 | filing |
| 3 Mar 2026filed 5 Mar 2026 | AMRX Amneal Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —36,232 at $0.00 | filing |
| 3 Mar 2026filed 5 Mar 2026 | AMRX Amneal Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —45,871 at $0.00 | filing |
| 3 Mar 2026filed 5 Mar 2026 | AMRX Amneal Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —23,544 at $0.00 | filing |
| 3 Mar 2026filed 5 Mar 2026 | AMRX Amneal Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —366,972 at $0.00 | filing |
| 3 Mar 2026filed 5 Mar 2026 | AMRX Amneal PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $246K18,502 at $13.31 | filing |
| 3 Mar 2026filed 5 Mar 2026 | AMRX Amneal PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | —45,871 | filing |
| 3 Mar 2026filed 5 Mar 2026 | AMRX Amneal Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —36,232 at $0.00 | filing |
| 3 Mar 2026filed 5 Mar 2026 | AMRX Amneal Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —45,871 at $0.00 | filing |
| 3 Mar 2026filed 5 Mar 2026 | AMRX Amneal Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —23,544 at $0.00 | filing |
| 3 Mar 2026filed 5 Mar 2026 | AMRX Amneal Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —366,972 at $0.00 | filing |
| 3 Mar 2026filed 5 Mar 2026 | AMRX Amneal PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $306K22,982 at $13.31 | filing |
News
No headline names them, or the companies they trade most, lately.